Evidence map›Paper›PMID 31555299›Full record

ArticleFrontiers in immunology2019

Low Avidity T Cells Do Not Hinder High Avidity T Cell Responses Against Melanoma.

Kalliopi Ioannidou, Olivier Randin, Aikaterini Semilietof, Hélène Maby-El Hajjami, Petra Baumgaertner, Dominique Vanhecke, Daniel E Speiser

Abstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Kalliopi IoannidouDepartment of Oncology, Lausanne University Hospital Center (CHUV), Lausanne, Switzerland.
Olivier RandinDepartment of Oncology, Lausanne University Hospital Center (CHUV), Lausanne, Switzerland.
Aikaterini SemilietofDepartment of Oncology, Lausanne University Hospital Center (CHUV), Lausanne, Switzerland.
Hélène Maby-El HajjamiDepartment of Oncology, Lausanne University Hospital Center (CHUV), Lausanne, Switzerland.
Petra BaumgaertnerDepartment of Oncology, Lausanne University Hospital Center (CHUV), Lausanne, Switzerland.
Dominique VanheckeDepartment of Oncology, Lausanne University Hospital Center (CHUV), Lausanne, Switzerland.
Daniel E SpeiserDepartment of Oncology, Lausanne University Hospital Center (CHUV), Lausanne, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The efficacy of T cells depends on their functional avidity, i. e., the strength of T cell interaction with cells presenting cognate antigen. The overall T cell response is composed of multiple T cell clonotypes, involving different T cell receptors and variable levels of functional avidity. Recently, it has been proposed that the presence of low avidity tumor antigen-specific CD8 T cells hinder their high avidity counterparts to protect from tumor growth. Here we analyzed human cytotoxic CD8 T cells specific for the melanoma antigen Melan-A/MART-1. We found that the presence of low avidity T cells did not result in reduced cytotoxicity of tumor cells, nor reduced cytokine production, by high avidity T cells.

Indexed as

AnimalsAntibody AffinityCancer VaccinesCD8-Positive T-LymphocytesCytotoxicity, ImmunologicHeterograftsHumansMART-1 AntigenMelanomaMiceTumor Cells, CulturedCancer VaccinesMART-1 Antigenadoptive T cell transferaviditycytotoxicity assayIFN-γ Elispot assaymelanomaT cell response

Identifiers

PMID31555299
PMCPMC6742971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.